EnGeneIC said today that the FDA granted orphan drug designation to the company’s targeted EDV nanocells for the treatment of glioblastoma multiforme.
The clinical stage biopharmaceutical company is developing bacterially-derived EDV nanocells as a nanoparticle, siRNA and miRNA delivery platform designed to target and kill tumor cells, while triggering the immune system’s natural anti-tumor response.
Get the full story at our sister site, Drug Delivery Business News.
The post EnGeneIC wins orphan drug designation for targeted nanocells appeared first on MassDevice.
from MassDevice http://ift.tt/2meZ4e1
Cap comentari:
Publica un comentari a l'entrada